Hims & Hers Health Inc. Faces Securities Class Action Over Alleged Sale of Knockoff Wegovy, Leading to Partnership Termination with <a href="https://laohu8.com/S/NVO">Novo Nordisk</a>
Hims & Hers Health Inc., a telehealth company based in San Francisco, is facing securities class action lawsuits following allegations that the company promoted and sold illegitimate versions of the weight-loss drug Wegovy. The lawsuits claim that Hims & Hers' actions endangered patients and posed a risk to its recently announced partnership with pharmaceutical giant Novo Nordisk. This partnership, centered on offering FDA-approved Wegovy through the Hims & Hers platform, was abruptly terminated by Novo Nordisk on June 23, 2025. The termination followed revelations of Hims & Hers' deceptive promotion practices and sales of knockoff products sourced from unregulated foreign suppliers. As a result of this news, Hims & Hers' stock price plummeted by 34.6%, highlighting the significant impact of the allegations on the company's market value. Investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, are encouraged to engage in the class action process before the lead plaintiff motion deadline on August 25, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hims & Hers Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1054580) on July 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.